Magan Medical Clinic, Inc.
telemedicine portal patient-portal

Dermatology

Magan Medical Clinic, Dermatology
420 W Rowland St, 2nd Floor
Covina, CA 91723

(626) 331-6411 Phone (Appointment Desk open M-F, 7:30 am-5:30 pm)
(626) 251-1552 Fax

 

Dermatology Staff
Our wonderful dermatology staff. Board certified dermatologist
 Charles Chiang, M.D., F.A.A.D. is in the center

 

We provide quality dermatology care with compassion. Our specialty is medical dermatology, including:

  • Acne (both teenage and adult onset; we are enrolled in iPledge if Accutane is needed)
  • Eczema / atopic dermatitis (in both children and adults)
  • Psoriasis
  • Skin cancer / skin exams
  • Moles
  • Warts / molluscum
  • Rosacea
  • Pigmentation disorders
  • Alopecia areata (autoimmune non-scarring hair loss)
  • Scarring hair loss (autoinflammatory scarring hair loss)
  • Phototherapy (we have a nbUVB booth and Dr. Chiang completed a phototherapy fellowship at UCSF)
  • Hives
  • Itching (pruritus)
  • Nail disorders

  • Note: Cosmetic treatments are not performed in Dermatology but instead by Maganís Medical Aesthetics Laser Center.

If you have psoriasis or hair questions, Dr. Chiang possesses special expertise. He completed fellowships in both fields at University of California, San Francisco where he saw a wide spectrum of patients (including the most severe), performed clinical trials, and published research.

We take pleasure in serving our community including Covina, West Covina, San Dimas, Rancho Cucamonga, Baldwin Park, Azusa, Glendora, Upland, El Monte, Duarte, Monrovia, Arcadia, La Puente, and Diamond Bar.

Same day appointments often available. No referral is necessary if you have PPO insurance. We accept a wide range of insurance plans (unfortunately, we do not accept Medi-Cal as primary insurance, only as secondary insurance).

For appointments, please call (626) 331-6411. We look forward to serving you!


 

"Whatís New in..."

A monthly column by Dr. Chiang

 

June 2017

What's New in Rosacea

What's new in Rosacea

There is a new topical therapy for rosacea called Rhofade (oxymetazoline) cream. While the FDA approved it in January, it has only been available at pharmacies recently. It is best used for the redness of rosacea (there are plenty of other medications for the acne-like bumps that are treated separately). It is a cream applied once daily that works by constricting blood vessels (technically called an alpha adrenergic agonist). It seems to be an improvement over a similar product called Mirvaso as it seems to cause less rebound (when a medication constricting the blood vessels wears off, there is potential that blood will rush into the area faster than before, causing increased redness and burning sensations. Iíve had some patients experience that with Mirvaso. Anecdotally, it seems much rarer with Rhofade).

I am not aware of the full clinical trial data being published. That being said, the FDA product insert summarizes that 489 study subjects were treated over 4 weeks. A separate up to 1 year clinical trial enrolled 440 subjects. Efficacy was good. However, the redness rarely completely resolved. Adverse reactions were quite low with 3% or fewer subjects experiencing rashes, flares, itching, redness, and discomfort.

As with most new products, it is only available as a brand name. No generic is available. Thus, the usual caveats that the copay may be high, it might be completely rejected by insurance, or I may recommend using a specialty pharmacy that is experienced in brand name medication insurance paperwork for a higher success rate. I have zero financial ties with any of these specialty pharmacies.

If you have rosacea or other skin issues, please make an appointment for dermatology consultation at (626) 331-6411 to discuss your options.

Charles Chiang, MD, FAAD
Board Certified Dermatologist

References:

- Waldorf HA, et al. Getting the red out: Expert tips Practical Dermatology 2017
- Prescribing information. Rhofade (oxymetazoline). https://www.allergan.com/assets/pdf/rhofade_pi.pdf Last accessed 5/29/17

For archives, click here.